Authorities in 27 European countries have approved ALK's tablet-based vaccine against grass pollen allergy, GRAZAX®, for treatment of children and adolescents (5 - 17 years old) suffering from grass pollen induced hay fever. The approval of GRAZAX® for children is a major milestone in the development of tablet-based allergy vaccines as it makes causal allergy treatment available to an important patient segment. Today, most children suffering from grass pollen allergy are only treated with symptom-relieving medications, such as oral antihistamines or nasal steroids, which treat the symptoms but not the cause of the disease. GRAZAX® is the first allergy tablet to treat the underlying cause of grass pollen allergy with documented persistent effect after completion of treatment. GRAZAX® is now also the first allergy tablet of its kind to be approved for treatment of children. In September 2006, GRAZAX® was approved in Europe for adult patients. This announcement does not change ALK's financial outlook for 2008. ALK-Abelló A/S Jens Bager President and CEO For further information please contact: Jens Bager, President and CEO, tel. +45 4574 7576 Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525 Press: Jacob Frische, tel +45 4574 7551, mobile +45 2224 7551 For further information, please see attached pdf-file.